Creyon Bio

Creyon Bio is a precision biotechnology company that develops on-demand oligonucleotide-based medicines (OBM) for patient populations of all sizes—from one to millions. Oligonucleotides are short single-stranded DNA/ribonucleic acid (RNA) molecules that are used in treating gene defects and metabolic disorders. The company’s AI and machine learning-based platform gathers, builds, and analyzes large datasets to identify effective designing and engineering pathways across various drug modalities, such as small interfering RNA (siRNA), DNA, and RNA editing systems, to treat both common and rare diseases.

Creyon’s OBMs will directly target the disease-causing molecules and genes, which will enable the development of precision medicines on-demand, thus reducing and ultimately eliminating the time between diagnosis and treatment. It is pursuing partnerships with disease organizations and patient advocacy groups, to build on its datasets and develop novel therapeutics. 

Creyon Bio, founded in 2019, emerged from stealth in March 2022, raising USD 40 million in seed and Series A financing to develop its AI platform and establish its internal pipeline.